Genelux Corporation
TrialRedline tracks 2 clinical trials sponsored by Genelux Corporation: 1 Phase 3, 1 Phase 2.
Company identity has not yet been verified
2Trials in this database
1Recorded changes · last 12 months
2Recruiting trials
Which trial dates moved later?
Genelux clinical trials we track
Check company identity sourcePhase 3 1 trial
Phase 2 1 trial
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Trial details
- Registry ID
- NCT06463665
- Drugs studied
- Docetaxel, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Olvimulogene nanivacirepvec, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab and 1 more
Drugs in these trials
Names as written in the registry records.
- Bevacizumab (or biosimilar) 1 trial
- Docetaxel 1 trial
- Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC 1 trial
- Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin 1 trial
- Olvimulogene nanivacirepvec 1 trial
- olvimulogene nanivacirepvec 1 trial
- Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab 1 trial
- Platinum chemotherapy: carboplatin (preferred) or cisplatin 1 trial
- Platinum chemotherapy: carboplatin or cisplatin 1 trial
Primary completion date changed
Before: Jun 2026. After: Dec 2026.